Global Insulin Drug and Delivery Technology Markets Report 2022: Historic Market Revenue for 2020 and 2021, Estimates for 2022, and CAGR Projections Through 2027 - ResearchAndMarkets.com | Business Wire

2022-09-24 00:40:56 By : Mr. levi li

DUBLIN--(BUSINESS WIRE )--The "Global Markets for Insulin Drug and Delivery Technologies" report has been added to ResearchAndMarkets.com's offering.

The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes the market trends of insulin drug and delivery technologies with data from 2021, estimates from 2022, projections of compound annual growth rates through 2027 (forecast period 2022-2027), and regional markets of the insulin drug and delivery technologies.

This report will highlight the current and future market potential of insulin drug and delivery technologies along with a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints and opportunities will be covered in the current report. The report also covers market projections for 2026 and market share for key market players.

Insulin drug and delivery technologies are used to manage type 1 and type 2 diabetes. Expedient insulin delivery devices such as smart pens help diabetes patients optimize blood glucose control and minimize the risk of associated health issues. Advanced insulin delivery devices offer better patient conformity.

The traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens due to the latter's portability, greater dosage accuracy, built-in memory, larger dosages and ease of use. There have been no major breakthrough in traditional syringes and pumps.

Major makers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Key manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Viatris Inc.

Market growth is attributed to factors such as the increasing incidence of diabetes and novel insulin drug and delivery technologies. The global market for insulin drug and delivery technologies is segmented by device type, insulin type and region.

In this report, the market has been segmented based on device type, insulin type and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens and others. Insulin types include long-acting, rapid-acting, premixed insulins, intermediate-acting and short-acting.

Geographic regions covered include North America, Europe, Asia-Pacific and the rest of the world (RoW). Individual countries covered include the U.S., Germany, the U.K., Italy, France, Japan, China and India.

Descriptive company profiles of key manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG

1.2.1 Disease Symptoms and Risk Factors

1.4 Reasons for Doing this Study

1.5 What's New in this Update?

3.1.2 Smart Insulin Drug Delivery Technologies

3.1.3 Painless Insulin Drug Delivery Technologies

3.3.1 Inorganic Strategies Amongst Market Players

Chapter 5 Regulatory Landscape and Reimbursement Scenario

5.1.1 U.S. Regulations for Medical Devices

5.1.3 European Regulations for Medical Devices

5.1.5 Asia-Pacific Regulations for Medical Devices

5.2.2 Pricing and Reimbursement for Medical Devices

5.2.3 Pricing and Reimbursement for Pharmaceuticals

Chapter 6 Impact of Covid-19 on Market

6.2.1 Impact on Market for Insulin Drug and Delivery Technologies

Chapter 7 Market Breakdown by Device Type

Chapter 8 Market Breakdown by Insulin Type

Chapter 9 Market Breakdown by Region

Chapter 10 Analysis of Market Opportunities

For more information about this report visit https://www.researchandmarkets.com/r/paod2q

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900